 |
 
Gammopathies and the Kidney and Thrombotic Microangiopathy
Flash slide/audio
(ASN Board Review, August, 2008)
Falk: What is the pathogenesis of amyloidosis? What are the most common types? What causes differential tissue deposition? How does this look on biopsy? How does one separate AL-amyloidosis
from light chain deposition disease? How useful are serologic tests (immunoelectrophoresis) and biopsy? Is stem cell transplant still indicated in 2008-2009? What did the RCT by Jaccard et al show?
If so, under what circumstances? What about secondary, AA-amyloid? Does eprodisate help? How does the clincal picture of multiple myeloma vary depending on site of light chain deposition? Is
plasmapheresis indicated in an AKI situation due to myeloma? How do fibrillary GN and immunotactoid GN differ? For which one does one have to worry about ruling out CLL? How is TPP different from HUS?
What type of nephropathy does sunitinib cause? Is testing from ADAMTS13 useful? Is plasma exchange for TTP useful? What about rituximab? How is complement factor H involved in atypical HUS? What's new
in HUS caused by toxin-producing E. coli?
(more...)
|
Shades of Grey: Key Questions in the Future of Treatment for CKD-Related Anemia
Flash slide/audio
(ASN Board Review, August, 2008)
Schmidt: What are current estimates of CKD in the US population and
the projected changes in the nephrology workforce? What are opportunities
for improving care, re Hb levels, AV access, dietitian consultation? What
are the results of a multidisciplinary approach to CKD? What constitutes
the multidisciplinary team and what are their roles? Toto: How do
observational and randomized trials differ in terms of benefits of more
complete anemia correction? Specifically, what did each type of trial
show in terms of CV endpoints, LV mass index, and quality of life? What is
the TREAT study and how will it add to our knowledge in this area?
Norris: How might the FDA black box warnings re ESAs pertaining to
cancer and deep vein thrombosis impact CKD patients? How does the KDOQI
2007 anemia update differ from the FDA black box warnings?
(more...)
|
The ESA Controversy: The Role of Intravenous Iron
Flash slide/audio
(ASN Board Review, August, 2008)
Ganz: What are the 3 means by which hepcidin levels are regulated? What is ferroportin and where does it act? What are physiologic and pathologic conditions in which hepcidin is either high or
low? Agarwal: What is the rationale for routine iron maintenance therapy as opposed to a load-and-hold strategy? What were results of studies targeting higher TSAT and/or allowing higher serum
ferritin levels? What are potential advantages of adding iron to the dialysate? How much iron do dialysis patients need in a typical year? Besarab: What are the most recent FDA guidelines re
ESA use? What does recent reanalysis of the CHOIR trial suggest regarding the importance of ESA dose and adverse outcomes? What is the basis of the time lag in Hb response after changes in ESA dose?
How can one minimize Hb variability? What effect does IV iron therapy have on ESA requirements?
(more...)
|
 |
 |
 |
|
|
Using Teamwork for Effective Management of CKD and Mineral and Bone Disorders
Craig B. Langman, MD and Kim Alleman, MS, RN, FNP-BC, CNN
(ANNA Fall Symposium, Chicago, IL. September, 2008.) 1.25 CNE
Langman: How has FGF23 changed the way we look at phosphate and vitamin D hydroxylation in CKD? Is FGF23 a risk marker for mortality? If so, can it be reduced by lowering serum phosphate? How
effective are various P-binders? How does serum phosphate relate to survival and vascular calcification? What did Treat to Goal, the Takei study, and RIND show with respect to calcification and
P-binders? How does treatment with P-binders affect calcification in predialysis patients? What are the nontraditional effects of sevelamer, and how might these impact on calcification? How is bone
remodeling linked to vascular calcification? How do P-binders compare re mortality? How might vitamin D deficiency affect mortality in CKD? How prevalent are low levels of 25-D and 1,25-D? How might
vitamin D affect cardiovascular function? What do observational studies show re Vitamin D treatment and survival in CKD?
Alleman: What are the goals of treatment in CKD-MBD? What are our current target lab values? How well or how poorly are we doing in achieving these targets? How can we put together an
effective collaborative approach to manage CKD-MBD? What are the team members and what are their roles? What are useful methods to promote collaboration?
|
|
 |
Annual Dialysis Conference 2008
now in MP3
|
AUDIOFILE
LIST (Annual Dialysis Conference 2008)
(38 talks)
Debate: How Patients Should Start Dialysis?
Dimitrios Oreopoulos, MD., Eli Friedman, MD., Carl Kjellstrand, MD
The Changing Environment of Anemia Management
Daniel Coyne, MD., Ajay Singh, MD., Ajay Singh, MD
Clinical HD Nursing
Arif Asif, MD., Susan Hossli, MSN, RN., Paul Smith, Lavonne Burrows, MSN, RN
Central Venous Catheter Update
Steve Schwab, MD., Hans-Dietrich Polaschegg, MD., Michael Tal, MD., William Salzer, MD., John Ross, MD
Adherence in Patients on Dialysis and Strategies for Success
Jean Kammerer, BSN, RN., Lori Grant, MEd, RD., Cynthia Russell, PhD, RN., Susan Finkelstein, LCSW
Joint Nutrition and Nursing Workshop
Cydney McQueen, PharmD
Vascular Access: Use of a Catheter As a Bridge to a Primary Vascular Access and Methods to Achieve Successful Outcomes with AV Fistulas
Arif Asif, MD., Deborah J. Brouwer, RN., Zbylut Twardowski, MD., Florin Gadalean, MD., Deborah Brouwer, RN
Preventing Morbidity and Mortality In PD
Anjali Saxena, MD., Mrinal Dasgupta, MD., John Van Stone, MD., Steven Guest, MD., Bengt Lindholm, MD., Paul Kimmel, MD., Rajnish Mehrotra, MD., Fredric Finkelstein, MD
Basic Nephrology Nursing
Linda Dickenson, RN., Rosemary Leitch, RN
Patient Education
Linda Dickenson, RN., Rosemary Leitch, RN
|
ASN Renal Week 2008
now in MP3
|
AUDIOFILE
LIST (ASN Renal Week 2008)
(13 talks)
Therapeutic Issues in Crescentic Glomerulonephritis and Vasculitis
LF Flores-Suarez, M Segelmark, U Specks
New Insights into Antibody-Mediated Rejection
KA Griffin, S Beddhu
Phosphorus: Bystander or Cause of Pathology?
RN Foley, DW Coyne, WF Finn
Membranous Glomerulonephritis
S Troyanov, G Remuzzi, JF Wetzels
Priming the Pump: Transitioning from CKD to ESRD
WD Mattern, CKT Farmer, LM Spergel, WF Clark
Literature Review - The Year in Nephrology: Hypertension and Metabolic Renal Syndrome
KA Griffin, S Beddhu
|
NANT 2008
now in MP3
|
AUDIOFILE
LIST (NANT 2008)
(6 talks)
Physiological Response to Dialysis
Charles Kaupke, MD
25 Years of advancing the technician and technologist
John Sweeny, CHT
Stages of CKD: What Happens Before Dialysis
Elaine Go, RN, NP, CNN
Role of the Dialysis Tech: How it has changed over 25 years
Susan Hansen, RN, CNN, CHT
Successfully Navigating Our Specialty's Changing Times
Gail Wick, MHSA, BSN, CNN
Myths and Facts: Why's and How's of Dialysis Technology
Forest Rawls, BS CHT, CCHT
|
 |
|
|
|
Hypertension, Cardiovascular:
Diuretic regimens in stage 4 CKD; Dyslipidemia and CKD mortality; High LDL marks better outcome in CKD; Dyslipidemia in CKD kids; Awareness and tx of dyslipidemia in CKD (NHANES); ASTRAL trial results
of intervention for RV HTN.
Dialysis, ESRD:
Kru in incident patients; Kru vs. depression; Survival in HD vs. PD; CAC predicts mortality; ADMA and mortality; Intradialytic exercise good; Actiwatch measurement of physical activity; SF12 vs. SF36;
Silica dust exposure and CKD; Screening for CKD in family members of dialysis patients; 300 vs. 600 irbesartan and echos; Phosphate vs. low protein affects progression; ONTARGET results in CKD subset;
Diet quality vs. albuminuria; High WBC marks mortality; HB acquired immunity and CDC HBV vaccination guidelines; Osteodystrophy and ESA responsiveness; Carbamylated darbo better;
Low 25D and mortality risk; Is tx with both 25D and paricalcitol needed?; Vitamin D levels and sepsis; Combined 25D and paricalcitol tx needed to prevent progression (rats); Is CTA018 a better VDR
agonist?; Slightly high PTH still mark CAC progression; VDRA treatment lowers oxidative stress; Hectorol vs. Zemplar and calcification in another rat study;
Pneumococcal infection declining; New assays for TB; T wave alternans and sudden death; High and low BP mark mortality in DOPPS; Anti-HTN drug use marks better survival; Which arterial stiffness
parameter to measure?; Pulse wave analysis: aTr better than Alx; Pregnancy in CKD; Albuminuria, cognition, and white matter in the elderly; ITCH registry analysis
Clinical Nephrology:
MMF plus low-dose prednisone for minimal change; Urinary oxalate not calcium marks stone risk in kids; Thiazides for IDH and hematuria in kids; Recurrent stone formers fail to drink more.
(more...)
|
|
 |
|
|
Pregnancy and the kidney
Maynard and Thadhani discuss how to estimate GFR and proteinuria in pregnancy, use of common renal medications in pregnancy, and finally, new information about the pathogenesis of preeclampsia ; in
the January 2009 issue of the J Am Soc Nephrol (JASN)
(more...) |
|
|
Transplant center regulations: ASTS vs. CMS
Abecassis and colleagues for the ASTS, vs. TE Hamilton for the CMS, discuss the new regulatory issues being implemented with regard to Transplant Centers;
in the December issue of the Am J Transplant.
(more...) |
|
|
Infection associated with tunneled hemodialysis catheters
Beathard and Urbanes talk about ointments, antibiotics, locks, and the antistaphylococcal effects of aspirin,
in the Nov/Dec issue of Seminars in Dialysis.
(more...) |
|
|
Effect of high altitude on CKD
Luks and colleagues from Denver speculate that altitude-related hypoxemia increases progression and CKD risk, and discuss kidney physiology, and why patients in the mountains with diabetes seem to
have more proteinuria; in the December 2008 issue of the J Am Soc Nephrol (JASN)
(more...) |
|
|
Hypertension-associated kidney disease: perhaps no more.
Is the increased risk of kidney disease in African Americans due to more hypertension or to some other genetic susceptibility. Freedman and Sedor explore these relationships
in the November 2008 issue of the J Am Soc Nephrol (JASN)
(more...) |
|
|
Acid-base disturbances in gastrointestinal disease
Gennari and Weise first review ion transport at all levels of the gut, and then show how this translates into acid-base disturbances with vomiting, inflammatory or secretary diarrhea, villous ademona,
and with ileostomy drainage;
from the November issue of the Clinical J Am Soc Nephrol (CJASN)
(more...) |
|
|
Nonphosphate-binding effects of sevelamer -- are they of clinical relevance?
Marangon, Lindholm, and Stenvinkel discuss the potential clinical importance of sevelamer's ability to lower LDL cholesterol, infrom endothelial function, and modulate inflammation and oxidative
stress;
from the Sept/Oct issue of Seminars in Dialysis.
(more...) |
|
|
Managing cancer risk and decision making after kidney transplantation.
Webster and colleagues discuss primary prevention, immunization, chemoprevention, and screening programs addressing management of posttransplant cancer risk;
in the November issue of the Am J Transplant.
(more...) |
|
|
Low molecular weight heparin for hemodialysis
Davenport talks about the problems, the benefits, and the costs of LMWH, which is now used extensively in Europe. In the October issue of
Hemodialysis International.
(more...) |
|
L-carnitine lowers oxidized LDL
96